Cover Image

Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

Abstract Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combinat...

Full description

Saved in:
Bibliographic Details
Main Authors: Jayna J Mistry (Author), Charlotte Hellmich (Author), Amelia Lambert (Author), Jamie A Moore (Author), Aisha Jibril (Author), Angela Collins (Author), Kristian M Bowles (Author), Stuart A Rushworth (Author)
Format: Book
Published: BMC, 2021-05-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.
Item Description:10.1186/s40364-021-00291-y
2050-7771

Similar Items